开放试验——从黑暗中来，光明至。 - Suppr

Suppr

超能文献

The OPEN trial-from the darkness, comes light.

作者信息

Pham Richard, Arulananda Surein

机构信息

Department of Medical Oncology, Monash Health, Clayton, Australia.

School of Clinical Sciences, Faculty of Medicine, Monash University, Clayton, Australia.

出版信息

Transl Lung Cancer Res. 2025 Aug 31;14(8):2912-2917. doi: 10.21037/tlcr-2025-363. Epub 2025 Aug 11.

DOI:10.21037/tlcr-2025-363

PMID:40948852

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC12432590/

Abstract

摘要

相似文献

The OPEN trial-from the darkness, comes light.开放试验——从黑暗中来，光明至。

Transl Lung Cancer Res. 2025 Aug 31;14(8):2912-2917. doi: 10.21037/tlcr-2025-363. Epub 2025 Aug 11.

A Prospective Phase II Trial of First-Line Osimertinib for Patients With EGFR Mutation-Positive NSCLC and Poor Performance Status (OPEN/TORG2040).一项针对表皮生长因子受体（EGFR）突变阳性、体能状态较差的非小细胞肺癌（NSCLC）患者的一线奥希替尼前瞻性II期试验（OPEN/TORG2040）。

J Thorac Oncol. 2025 May;20(5):665-675. doi: 10.1016/j.jtho.2024.12.027. Epub 2025 Jan 2.

Upfront osimertinib and as sequential therapy in patients with -mutant non-small cell lung cancer (NSCLC): benefit across patients groups in a real-world retrospective cohort-the smile study.奥希替尼一线治疗及序贯治疗携带 - 突变的非小细胞肺癌（NSCLC）患者：真实世界回顾性队列研究中各患者组的获益——微笑研究

Transl Lung Cancer Res. 2025 Jul 31;14(7):2427-2436. doi: 10.21037/tlcr-24-881. Epub 2025 Jul 21.

Osimertinib for patients with poor performance status and EGFR T790M mutation-positive advanced non-small cell lung cancer: a phase II clinical trial.奥希替尼治疗体力状况不佳且 EGFR T790M 突变阳性的晚期非小细胞肺癌患者：一项 II 期临床试验。

Invest New Drugs. 2020 Dec;38(6):1854-1861. doi: 10.1007/s10637-020-00943-0. Epub 2020 May 18.

Osimertinib for patients with EGFR T790M mutation-positive non-small-cell lung cancer and a poor performance status.奥希替尼用于 EGFR T790M 突变阳性、体能状况较差的非小细胞肺癌患者。

Jpn J Clin Oncol. 2019 Jul 1;49(7):671-675. doi: 10.1093/jjco/hyz041.

Rationale and protocol design of a phase II study of first-line osimertinib treatment for patients with poor performance status and EGFR mutation-positive non-small cell lung cancer (OPEN/TORG2040).一线奥希替尼治疗体力状态不佳和 EGFR 突变阳性非小细胞肺癌患者的 II 期研究的理由和方案设计（OPEN/TORG2040）。

BMC Cancer. 2022 Dec 15;22(1):1314. doi: 10.1186/s12885-022-10409-6.

Savolitinib plus osimertinib in epidermal growth factor receptor (EGFR)-mutated advanced non-small cell lung cancer with MET overexpression and/or amplification following disease progression on osimertinib: primary results from the phase II SAVANNAH study.赛沃替尼联合奥希替尼用于表皮生长因子受体（EGFR）突变的晚期非小细胞肺癌，这些患者在奥希替尼治疗疾病进展后出现MET过表达和/或扩增：II期SAVANNAH研究的主要结果

Ann Oncol. 2025 Aug;36(8):920-933. doi: 10.1016/j.annonc.2025.04.003. Epub 2025 Jun 2.

Risk Factors Associated with Suboptimal Real-World Outcomes in Patients with EGFR-Mutated Non-Small Cell Lung Cancer Treated with Front-Line Recommended Therapy.表皮生长因子受体（EGFR）突变的非小细胞肺癌患者接受一线推荐治疗后，与欠佳的真实世界治疗结果相关的风险因素

Adv Ther. 2025 May 29. doi: 10.1007/s12325-025-03234-3.

Impact of clinical features on the efficacy of osimertinib therapy in patients with T790M-positive non-small cell lung cancer and acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors.临床特征对T790M阳性非小细胞肺癌且对表皮生长因子受体酪氨酸激酶抑制剂获得性耐药患者奥希替尼治疗疗效的影响

J Thorac Dis. 2019 Jun;11(6):2350-2360. doi: 10.21037/jtd.2019.06.03.

First-line osimertinib for poor performance status patients with EGFR mutation-positive non-small cell lung cancer: A prospective observational study.一线奥希替尼治疗 EGFR 突变阳性非小细胞肺癌伴差一般状况患者：一项前瞻性观察研究。

Invest New Drugs. 2022 Apr;40(2):430-437. doi: 10.1007/s10637-021-01195-2. Epub 2021 Nov 22.

本文引用的文献

Rezivertinib versus gefitinib as first-line therapy for patients with EGFR-mutated locally advanced or metastatic non-small-cell lung cancer (REZOR): a multicentre, double-blind, randomised, phase 3 study.瑞泽替尼与吉非替尼作为表皮生长因子受体（EGFR）突变的局部晚期或转移性非小细胞肺癌患者一线治疗的疗效比较（REZOR）：一项多中心、双盲、随机、3期研究

Lancet Respir Med. 2025 Apr;13(4):327-337. doi: 10.1016/S2213-2600(24)00417-X. Epub 2025 Feb 3.

J Thorac Oncol. 2025 May;20(5):665-675. doi: 10.1016/j.jtho.2024.12.027. Epub 2025 Jan 2.

Adequate assessment yields appropriate care-the role of geriatric assessment and management in older adults with cancer: a position paper from the ESMO/SIOG Cancer in the Elderly Working Group.充分评估带来恰当照护——老年癌症患者的老年综合评估和管理作用：来自 ESMO/SIOG 老年肿瘤工作组的立场文件。

ESMO Open. 2024 Aug;9(8):103657. doi: 10.1016/j.esmoop.2024.103657. Epub 2024 Aug 19.

The clinical features and prognostic implications of the co-mutated TP53 gene in advanced non-small cell lung cancer.晚期非小细胞肺癌中 TP53 共突变的临床特征及其预后意义。

Clin Transl Oncol. 2024 Dec;26(12):3236-3245. doi: 10.1007/s12094-024-03533-1. Epub 2024 Jun 13.

Osimertinib with or without Chemotherapy in -Mutated Advanced NSCLC.奥希替尼对比含铂化疗用于 - 突变型晚期 NSCLC。

N Engl J Med. 2023 Nov 23;389(21):1935-1948. doi: 10.1056/NEJMoa2306434. Epub 2023 Nov 8.

Befotertinib (D-0316) versus icotinib as first-line therapy for patients with EGFR-mutated locally advanced or metastatic non-small-cell lung cancer: a multicentre, open-label, randomised phase 3 study.贝福替尼（D-0316）对比厄洛替尼用于表皮生长因子受体突变的局部晚期或转移性非小细胞肺癌患者的一线治疗：一项多中心、开放标签、随机、III 期研究。

Lancet Respir Med. 2023 Oct;11(10):905-915. doi: 10.1016/S2213-2600(23)00183-2. Epub 2023 May 24.

A narrative review of genetic biomarkers in non-small cell lung cancer: an update and future perspectives.非小细胞肺癌中遗传生物标志物的叙述性综述：最新进展与未来展望

AME Med J. 2023 Mar 30;8. doi: 10.21037/amj-2022-01. Epub 2023 Feb 2.

Lung adenocarcinoma promotion by air pollutants.空气污染促进肺腺癌。

Nature. 2023 Apr;616(7955):159-167. doi: 10.1038/s41586-023-05874-3. Epub 2023 Apr 5.

Retrospective analysis of independent predictors of progression-free survival in patients with EGFR mutation-positive advanced non-small cell lung cancer receiving first-line osimertinib.回顾性分析 EGFR 突变阳性的晚期非小细胞肺癌患者一线接受奥希替尼治疗的无进展生存期的独立预测因素。

Thorac Cancer. 2022 Oct;13(19):2741-2750. doi: 10.1111/1759-7714.14608. Epub 2022 Aug 18.

Furmonertinib (AST2818) versus gefitinib as first-line therapy for Chinese patients with locally advanced or metastatic EGFR mutation-positive non-small-cell lung cancer (FURLONG): a multicentre, double-blind, randomised phase 3 study.福莫替尼（AST2818）对比吉非替尼作为局部晚期或转移性 EGFR 突变阳性非小细胞肺癌中国患者的一线治疗药物（FURLONG）：一项多中心、双盲、随机 3 期研究。

Lancet Respir Med. 2022 Nov;10(11):1019-1028. doi: 10.1016/S2213-2600(22)00168-0. Epub 2022 Jun 2.

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验